Abstract:Natural killer (NK) cells have the unique capacity to lyse tumor cells without the need for antigen specific receptors. Modulation of NK cell cytokine, chemokine, and activating and inhibitory receptor expression using gene regimens represents an attractive strategy to further bolster NK cell anti-tumor activity for the purpose of NK cell immunotherapy. Current efforts in clinical-grade genetic modification of patient-derived cells, used in immunotherapy protocols, rely on stable transduction mediated by viral vectors. However, primary NK cells are notoriously difficult to transduce using viral vectors. Here we describe a lentiviral vector-based approach that results in an efficient, robust, and highly reproducible method of stable gene transfer into primary human peripheral blood-derived NK cells, which can subsequently be expanded ex vivo for adoptive infusion into humans. In vitro experiments established highly efficient transduction of ex vivo expanded NK cells could be achieved by activation of primary NK cells in vitro for 2-4 days in cytokine containing media followed by transduction of activated NK cells using LV vectors 2-3 days before integration into our existing ex vivo expansion protocol using irradiated EBV-LCL feeder cells. Unless NK cells were first activated in cytokine-containing media, LV transduction was unsuccessful. Cytokine activation in media containing IL-2 for 2-4 days was found to be sufficient to achieve high transduction efficiency, while additional supplementation of the media with IL-15 or IL-21 had negligible effects. NK cell transduction efficiency and viability with the use of RetroNectin® was uniformly superior to polycation-based transduction protocols. In experiments where NK cells were transduced with identical lentiviral constructs with 8 different promoter sequences driving expression of EGFP, PGK, EFS, and SV40 promoters consistently demonstrated the highest transduction efficiencies reproducibly in the range of 25-60%. Remarkably, when transduced NK cells were stimulated ex vivo using a clinical grade irradiated EBV-LCL feeder cell line, 100-1000 fold expansions of transduced NK cells could be achieved with sustained transgene expression over two weeks. Transduced and expanded primary NK cells remained highly cytotoxic against K562 tumor targets without developing functional deficiencies in degranulation, IFNγ, or TNFα production. These data establish a simple method to produce large numbers (>1011) of genetically modified clinical grade NK cells suitable for infusion. The protocol described herein overcomes previous difficulties described with common transduction techniques opening new avenues to investigate the impact of adoptive infusion of primary NK cells stably transduced to express a variety of different transgenes of interest.

A solution for highly efficient electroporation of primary cytotoxic T lymphocytes

An Optimized Non-T Cell Transfection System Based on HEK293FT Cells for CD3ζ Phosphorylation and Ubiquitination

A multiplexed microfluidic continuous-flow electroporation system for efficient cell transfection

Surviving High-Intensity Field Pulses: Strategies for Improving Robustness and Performance of Electrotransfection and Electrofusion

Optimized DNA electroporation for primary human T cell engineering

The challenging nature of primary T lymphocytes for transfection: Effect of protamine sulfate on the transfection efficiency of chemical transfection reagents

High-throughput continuous-flow microfluidic electroporation of mRNA into primary human T cells for applications in cellular therapy manufacturing

Efficient electroporation in primary cells with PEDOT:PSS electrodes

Setting optimal parameters for in vitro electrotransfection of B16F1, SA1, LPB, SCK, L929 and CHO cells using predefined exponentially decaying electric pulses

An efficient low cost means of biophysical gene transfection in primary cells

High-Efficiency Lentiviral Genetic Modification of Primary Human Natural Killer Cells

A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications

High-Throughput and Efficient Intracellular Delivery Method via a Vibration-Assisted Nanoneedle/Microfluidic Composite System

A Digital Microfluidic Platform for the Microscale Production of Functional Immune Cell Therapies

Generation of Tumor-activated T cells Using Electroporation

Research of the efficiency of electroporation transfect DNA into K562 cells

Transfection by Electroporation of Cancer and Primary Cells Using Nanosecond and Microsecond Electric Fields

Optimized two‐step electroporation process to achieve efficient nonviral‐mediated gene insertion into primary T cells

Achieving efficient clonal beta cells transfection using nanostraw/nanopore-assisted electroporation

Efficient Gene Transfection by Electroporation—In Vitro and In Silico Study of Pulse Parameters

Back to basics: Optimization of DNA and RNA transfer in muscle cells using recent transfection reagents